Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Fat Pad Derived Mesenchymal Stem Cells for ACL Reconstruction
NCT06798623Phase 1Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous mesenchymal stromal cells in anterior cruciate ligament injury, sponsored by Houston Methodist Research Institute. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 6 months and Knee Function at 6 months. Started Mar 2026; status: recruiting.
02
Drugs
autologous mesenchymal stromal cells
03
Conditions
anterior cruciate ligament injury
Beyond the preview
Go deeper on NCT06798623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798623.